Cargando…
p16 Mutation Spectrum in the Premalignant Condition Barrett's Esophagus
BACKGROUND: Mutation, promoter hypermethylation and loss of heterozygosity involving the tumor suppressor gene p16 (CDKN2a/INK4a) have been detected in a wide variety of human cancers, but much less is known concerning the frequency and spectrum of p16 mutations in premalignant conditions. METHODS A...
Autores principales: | Paulson, Thomas G., Galipeau, Patricia C., Xu, Lianjun, Kissel, Heather D., Li, Xiaohong, Blount, Patricia L., Sanchez, Carissa A., Odze, Robert D., Reid, Brian J. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2585012/ https://www.ncbi.nlm.nih.gov/pubmed/19043591 http://dx.doi.org/10.1371/journal.pone.0003809 |
Ejemplares similares
-
NSAIDs Modulate Clonal Evolution in Barrett's Esophagus
por: Kostadinov, Rumen L., et al.
Publicado: (2013) -
Warburg and Crabtree Effects in Premalignant Barrett's Esophagus Cell Lines with Active Mitochondria
por: Suchorolski, Martin T., et al.
Publicado: (2013) -
NSAID use and somatic exomic mutations in Barrett’s esophagus
por: Galipeau, Patricia C., et al.
Publicado: (2018) -
Correction to: NSAID use and somatic exomic mutations in Barrett’s esophagus
por: Galipeau, Patricia C., et al.
Publicado: (2019) -
Within‐patient phylogenetic reconstruction reveals early events in Barrett’s Esophagus
por: Smith, Lucian P., et al.
Publicado: (2020)